Peptides for Intervertebral disc disease (IVDD) in Dogs
The short answer
For intervertebral disc disease (ivdd) in dogs, the compounds under investigation are BPC-157, TB-500 — of which BPC-157 has the strongest evidence base, graded emerging. Degeneration and herniation of spinal discs causing pain, weakness, or paralysis — a defining risk in chondrodystrophic breeds. No compound described here is FDA-approved for this use in dogs, and none should be started without veterinary involvement.
About the condition
IVDD occurs when the cushioning disc between vertebrae degenerates and its material displaces into the spinal canal, compressing the cord. In chondrodystrophic breeds — Dachshunds above all — disc degeneration begins in early adulthood, and a herniation can happen during entirely ordinary activity. Presentation ranges from a reluctance to jump to acute paralysis, and severe cases are surgical emergencies where time to decompression drives the outcome. Research interest in peptides here focuses on the recovery period and inflammatory management around the injured cord, always as an adjunct to proper neurological assessment rather than a substitute for it.
Compounds investigated for this condition
Ranked by strength of the published evidence.
The only peptide on this site with published canine pharmacokinetic data.
BPC-157 is a short chain of fifteen amino acids originally identified in gastric juice. Research describes it encouraging the growth of new blood vessels into damaged tissue, which is the rate-limiting step in most healing. Studies also report a protective effect on the lining of the gut. It is the one compound here with a published pharmacokinetic study performed in dogs, which is why it appears first on almost every canine protocol.
Full BPC-157 profile, dosing and safety →The most established compound in veterinary research, with equine work dating to the early 2000s.
TB-500 is a synthetic fragment of thymosin beta-4, a protein found naturally throughout the body and concentrated at wound sites. The active portion binds actin, the structural protein cells use to move. Research describes this helping repair cells migrate into damaged tissue, alongside new blood vessel formation and collagen laydown.
Full TB-500 profile, dosing and safety →Critical safety notes
These apply to the compounds listed above and should be read before considering any of them.
⚠ TB-500: Contraindicated with active cancer
TB-500 is associated with promoting angiogenesis and cell migration in preclinical models — the same two processes tumours depend on to grow and spread. Any dog with a known or suspected malignancy should be screened and cleared before this compound is considered.
Breeds with elevated predisposition
Breed affects both the likelihood of this condition and, in some cases, which compounds are safe.
Common questions
What peptides are used for intervertebral disc disease (ivdd) in dogs?+
BPC-157, TB-500 are the compounds investigated for intervertebral disc disease (ivdd) in dogs. BPC-157 carries the strongest evidence of these, graded as emerging evidence. None are FDA-approved for this use in dogs.
Do peptides actually help intervertebral disc disease (ivdd) in dogs?+
The honest answer is that the canine evidence is limited. Degeneration and herniation of spinal discs causing pain, weakness, or paralysis — a defining risk in chondrodystrophic breeds. The compounds investigated here have mechanistic support and, in some cases, published animal data — but controlled clinical trials in dogs with intervertebral disc disease (ivdd) have not been conducted. Any use is investigational and belongs in a conversation with your veterinarian rather than a decision made independently.
Which breeds are most affected by intervertebral disc disease (ivdd)?+
Dachshund, French Bulldog, Beagle, Cocker Spaniel, Shih Tzu carry elevated predisposition to intervertebral disc disease (ivdd). Breed matters beyond risk of the condition itself — some breeds carry genetic traits that change which compounds are safe, such as the MDR1 mutation in herding breeds and copper storage disease in Bedlington Terriers and certain Labrador lines.
References
- 1.CANINE STUDYHe L, et al. Pharmacokinetics, distribution, metabolism and excretion of BPC 157 in rats and dogs. Frontiers in Pharmacology, 2022. PMID 36588722
- 2.CANINE STUDYXu C, et al. Preclinical safety evaluation of body protective compound-157. Regulatory Toxicology and Pharmacology, 2020. PMID 32334036
- 3.Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine. Orthopaedic Journal of Sports Medicine, 2025. PMC12313605
- 4.Gwyer D, Wragg NM, Wilson SL Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 2019. PMID 30915550
- 5.Jozwiak M, et al. Multifunctionality of BPC 157: Literature and Patent Review. Pharmaceuticals, 2025. PMC11859134
- 6.CANINE STUDYJournal of the American Holistic Veterinary Medical Association Case report: canine stifle injury managed with BPC-157 and TB-500. JAHVM, 2023. View source
- 7.Kleinman HK, Sosne G Thymosin beta 4 promotes dermal healing: animal studies. Annals of the New York Academy of Sciences, 2010. PMID 20536453
- 8.Goldstein AL, Hannappel E, Sosne G, Kleinman HK Thymosin beta-4: a multi-functional regenerative peptide. Expert Opinion on Biological Therapy, 2012. PMID 22074294
- 9.Kwok WH, et al. Doping control analysis of TB-500 in equine urine and plasma. Journal of Chromatography B, 2013. PMID 23084823
- 10.Esposito S, et al. TB500/TB1000: understanding misbranded drugs. Drug Testing and Analysis, 2022. View source
Where to source research peptides
Compound quality is the variable most owners underestimate. Purity, accurate peptide content, and correct labelling determine whether any published dosing figure means anything at all. Pet & Peps Research publishes third-party testing on the compounds covered in this guide and supports this site.
Educational information — not veterinary medical advice
Everything on this page is compiled from published peer-reviewed literature for educational and research purposes. It does not establish a veterinarian-client-patient relationship (VCPR) and is not a substitute for veterinary examination and diagnosis. Most compounds described here are investigational or used off-label and are not FDA-approved for these purposes in dogs. Extralabel drug use in animals requires a valid VCPR and the direct supervision of a licensed veterinarian under AMDUCA (21 U.S.C. §360b). Dosing figures are reported as they appear in the source literature and are not recommendations.